Divine Aleru, Microbiome Signatures Research Coordinator

This review explores how gut microbiota modulation influences ovarian aging and presents potential therapies like fecal microbiota transplantation and probiotics to prevent or alleviate ovarian aging, offering new strategies for preserving reproductive health.

This review examines the relationship between gut microbiota and ovarian aging, highlighting microbial dysbiosis as a key factor in ovarian function decline. It explores microbiota-based therapies like MT to delay ovarian aging and discusses the role of dietary and pharmacological interventions.

This study demonstrates the effectiveness of ultrasound-guided hUC-SC exosome injection in restoring ovarian function and fertility in OI rat models, offering a new therapeutic approach for women with OI.

This study demonstrates that metformin protects against chemotherapy-induced ovarian failure by reducing inflammation, oxidative stress, and senescence in granulosa cells via the MPK/PAR-γ/IRT1 pathway.

The review discusses the therapeutic use of hormone replacement therapy (RT) for managing OI and early menopause, highlighting its benefits in preventing complications like osteoporosis, cardiovascular disease, and depression.

This study identifies 27 metabolites linked to primary ovarian insufficiency (OI), revealing novel metabolic pathways and offering insights into OI biomarkers and therapeutic targets.

This study identifies 33 serum metabolites, including N-acetylalanine, linked to an increased risk of primary ovarian insufficiency (OI), offering new insights into the disease’s genetic and metabolic causes.

This study identifies metabolic disruptions in OI, including altered amino acid and lipid metabolism. Key metabolites such as acetoacetate and DCA were found to be potential biomarkers, shedding light on the oxidative stress and mitochondrial dysfunction involved in OI.

This study examines the metabolic profile of women with premature ovarian insufficiency, finding significant changes in lipid and glucose metabolism. The results underscore the importance of early metabolic screening and management to reduce cardiovascular and metabolic risks associated with OI.

This study investigates the metabolic differences in women with premature ovarian insufficiency (OI), highlighting increased waist circumference, cholesterol, and glucose levels. It underscores the importance of early metabolic screening and management to address the elevated cardiovascular risk associated with OI.